MedTrace Logo

A Study to Evaluate the Safety and Pharmacokinetics of AG2304 Compared to Coadministration of AG23041 and AG23042

NCT06916169 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2025-04-08

No results posted yet for this study

Summary

The objective of this study is to evaluate the pharmacokinetic characteristics of AG2304 in healthy subjects.

Conditions

  • Pharmacokinetics

Interventions

DRUG

AG2304

AG2304, Single-dose Oral Administration

DRUG

AG23041 and AG23042

AG23041/AG23042, Single-dose Oral Administration

Sponsors & Collaborators

  • Ahn-Gook Pharmaceuticals Co.,Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-08-31
Primary Completion
2025-09-30
Completion
2025-09-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06916169 on ClinicalTrials.gov